SPECIAL NOTICE
Q -- An expanded investigation of pesticide use and circulating markers of nephrotoxicity associated with malignant and non-malignant kidney disease
- Notice Date
- 6/24/2020 2:14:41 PM
- Notice Type
- Special Notice
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- NIH NCI ROCKVILLE MD 20852 USA
- ZIP Code
- 20852
- Solicitation Number
- 75N91020Q00115
- Response Due
- 7/8/2020 12:00:00 PM
- Archive Date
- 07/23/2020
- Point of Contact
- Miguel Diaz, Phone: 2402765439
- E-Mail Address
-
miguel.diaz@nih.gov
(miguel.diaz@nih.gov)
- Description
- Department of Health and Human Services, National Institutes of Health (NIH), National Cancer Institute (NCI), Office of Acquisitions, 9609 Medical Center Drive, Room 1E144, Bethesda, MD 20892, UNITED STATES. (Non-USPS mail such as Fedex, UPS and other private carriers please use Rockville, MD 20850) National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Occupational and Environmental Epidemiology Branch (EEB) seeks to procure a study of nephrotoxicity markers, on a sole source basis, from Brigham and Women�s Hospital of 75 Francis Street Boston, MA 02115 This acquisition will be processed under FAR Part 12 � Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-1 (b)(1)(i) using simplified acquisition procedures for commercial acquisitions.� The North American Industry Classification System code is 541990 and the business size standard is $15.0M.� The purpose of this acquisition is to measure markers of nephrotoxicity, including urinary kidney injury molecule 1 (KIM-1), and serum soluble urokinase-type plasminogen activator receptor (SuPAR), Cystatin C, and creatinine using urine and blood samples collected from Agricultural Health Study (AHS) population. The primary objective of this study is to follow-up on recent findings from NCI within the Agricultural Health Study that showed an association between use of certain pesticides and risk of renal cell carcinoma.� By measuring markers of nephrotoxicity that have been previously been associated with renal cell carcinoma risk, among individuals with well-defined exposure histories, this work can provide evidence for the biological plausibility between these exposures and the development of renal cell carcinoma.� The contractor shall measure levels of circulating markers of nephrotoxicity among individuals with detailed exposure records of exposures previously identified to be associated with the development of renal cell carcinoma within the AHS population by performing the following tasks:� Document the receipt of all serum samples in a MS Excel file with the unique ID of each sample Perform assays measuring serum levels of nephrotoxicity markers for each sample submitted Record assay results, test date, batching information, and quality control data (if applicable) in the Excel file Provide NCI investigators with a copy of the Excel data file upon completion. The Brigham and Women's Hospital is currently conducting analyses of many of the proposed circulating markers of nephrotoxicity (e.g., KIM-1 and Cystatin C) for another effort within NCI. In order to ensure scientific comparability across studies, the same laboratory technique and group is required to eliminate any lab to lab variation. Furthermore, the rationale for using KIM-1 to prospectively assess risk of developing kidney cancer was developed and published by the Brigham and Women's Hospital (Scelo et al., 2018; PMCID: PMC6239904) making them the ideal laboratory to perform the proposed study.� Since the assays for the previous study of nephrotoxicity markers in the AHS were conducted at the Brigham and Women's Hospital, for scientific comparability, it is required that the assays are performed by the same laboratory for this expanded study.� Brigham and Women�s Hospital has been identified as the only known source capable of fulfilling the requirements of this procurement. This notice is not a request for competitive quotation. However, if any interested party, especially small business believes it can meet the above requirement, it may submit a capability statement for the Government to consider. The response and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement.� Responses must be received in the contracting office by 3:00 PM ET, on July 08, 2020.� All responses and questions must be via email to Miguel Diaz, Contracting Officer at miguel.diaz@nih.gov.� A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.� In order to receive an award, contractors must be registered and have valid certification through SAM.GOV and have Representations and Certifications filled out. Reference: 75N91020Q00115 on all correspondence.
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/c0619b3cc49a448b9e8fc347eec95f3a/view)
- Place of Performance
- Address: Bethesda, MD 20892, USA
- Zip Code: 20892
- Country: USA
- Zip Code: 20892
- Record
- SN05701069-F 20200626/200624230147 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |